Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 531 versus placebo in splenectomy-refractory ITP
2004-000174-31Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in immune thrombocytopenia (ITP) comparing AMG 531 with Placebo (2 arms). Primary endpoint: Incidence of durable platelet response. Started Feb 2005; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2004-000174-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000174-31.